456 results about "Herpes simplex virus" patented technology

The invention involves novel drug use of six-rowed chrysanthemum plant extracts which is used to treating herpes simplex virus (type 1 and / or type 2) and various disease caused by hepatitis B virus infection. The six-rowed chrysanthemum plant extracts is prepared by six-rowed chrysanthemum plant fresh or dry goods through the refining of alcohol-water extraction, column chromatography, alcohol solvent elution, the amount of caffeoyl guinic acid chemical compound is below 30%. The six-rowed chrysanthemum plant extracts prepared in the invention has significant function of inhibiting herpes simplex virus with type 1 (HSV-1), herpes simplex virus type 2 (HSV-2) and hepatitis B virus (HBV) replication, and can reduce effectiveness of HBV e antigen (HBeAg) in the HepG 2.2.15 cell lines, it can be used for treatment various disease caused by said correlate virus infection.

A packaging cell line capable of complementing recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells (e.g., primary human retinoblasts, primary human embryonic kidney cells and primary human amniocytes) which are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 (ECACC deposit number 96022940), which cell expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The new cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell line can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies. In addition, the cell lines are useful for producing human viruses other than adenovirus such as influenza virus, herpes simplex virus, rotavirus, measles virus.

The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both γ134.5 genes of the virus have been deleted and each replaced with an interferon-resistance gene that is expressed as an immediate-early gene. The present invention also relates to a pharmaceutical composition that includes the modified herpes simplex virus of the present invention and a pharmaceutically acceptable vehicle for in situ administration to tumor cells. Also provided in the present invention are methods for killing tumor cells in a subject and for immunizing a subject against an infectious disease, cancer, or an autoimmune disease that involve administering to a subject the modified avirulent, oncolytic herpes simplex virus of the present invention.

The use of Herpes Simplex Virus (HSV) in the treatment of tumour by extratumoural administration of HSV, and the use of HSV in treatment of tumour by combination therapy with a pharmaceutical wherein the HSV and / or pharmaceutical is administered at an extratumoural location, is disclosed.

Compositions including an isolated Bacillus species, spores or an extracellular product of B. coagulans, suitable for topical application, for inhibiting growth of yeast, fungus, bacteria or Herpes simplex virus are disclosed. Methods of inhibiting growth of yeast, fungus, bacteria or Herpes simplex virus by topical application of compositions that include an isolated Bacillus species, spores or an extracellular product of a B. coagulans strain are disclosed.

Compositions including an isolated Bacillus species, spores or an extracellular product of B. coagulans, suitable for topical application, for inhibiting growth of yeast, fungus, bacteria or Herpes simplex virus are disclosed. Methods of inhibiting growth of yeast, fungus, bacteria or Herpes simplex virus by topical application of compositions that include an isolated Bacillus species, spores or an extracellular product of a B. coagulans strain are disclosed.

A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide.

An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.

The use of Herpes Simplex Virus (HSV) in the treatment of tumour by extratumoural administration of said HSV, and the use of HSV in treatment of tumour by combination therapy with a pharmaceutical wherein the HSV and / or pharmaceutical is administered at an extratumoural location, is disclosed.

This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.

Improved topical treatment of active phase lesions resulting from recurrent viral infection by herpes simplex virus which includes the use of two primary agents, namely, an aqueous solution of benzalkonium halide, preferably benzalkonium chloride, and a dry form of the herb Echinacea purpurea, preferably in powder form. Active phase herpes lesions are wetted with the benzalkonium chloride solution and dusted with the powder form of Echinacea purpurea to create a coating on the wetted lesion surface. The coating is maintained on the lesion throughout treatment, and unexpected rapid resolution of the lesions results.

The invention belongs to the technical field of digital image processing and pattern recognition and particularly relates to a plant disease and pest detection method based on SVM (support vector machine) learning. The plant disease and pest detection method comprises the following steps: acquiring a large number of regularly grown plant leaves and the plant leaves with diseases and pests from a large number of monitoring videos of agricultural scenes; extracting a part of pictures of the regularly grown plant leaves and the plant leaves with diseases and pests as samples; extracting characteristics [including color characteristic, HSV (herpes simplex virus) characteristic, edge characteristic and HOG (histogram of oriented gradient) characteristic] of each leaf picture; combining the characteristics into characteristic vectors; training the characteristic vectors of each leaf picture through an SVM learning method; forming a classifier after training; and detecting the large number of plant leaf pictures by the classifier to detect whether diseases or pests occur to the plant leaves. Compared with a biologic plant disease and pest detection method, the plant disease and pest detection method based on the SVM learning is higher in real time and easier to implement; and the shortcoming of detecting the plant diseases and pests by working in the fields is overcome.

The present invention is directed oncolytic Herpes simplex-l viruses whose replication is controlled using a tetracycline operator / repressor system. The invention also includes DNA sequences used in making the viruses and methods in which these viruses are used in the treatment of cancer patients with solid tumors.

The present invention provides a herpes simplex virus strain which lacks a functional ICP34.5 gene and a functional ICP27 gene. It also provides the use of a herpes simplex virus strain which lacks a functional ICP34.5 gene and a functional ICP27 gene in the treatment of disorders of, or injuries to, the nervous system of a mammal.

This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.

Compositions, formulations, and methods for the treatment or prevention, or decreasing the frequency of transmission of a virus (such as human immunodeficiency virus type 1 (HIV-1), Herpes Simplex virus type 1 (HSV1), or Herpes Simplex Virus Type 2 (HSV2), or other virus), or a bacterial infection (such as Trichomonas vaginalis, Neisseris gonorrhoeae Haemopholus ducreyl, or Chlamydia trachomatis, or other bacterial species), or a fungal infection, using an anionic cellulose- or acrylic-based oligomer, polymer, or copolymer. The present invention also includes administering a therapeutically effective amount of said oligomer, polymer, or copolymer, or a pharmaceutically acceptable salt thereof, or with a pharmaceutically acceptable carrier or diluent, thereof. The invention relies on the unique biochemical substitution of the cellulose or acrylic backbone such that the resultant molecule can remain molecularly dispersed in solution (or gel or other formulation) and mostly dissociated over a wide range of physiological microenvironments, such as the low pH found within the vaginal lumen, preferably from a pH of 14 to below 3.5. These specific substitutions also impart on the resultant molecule potent antiviral, anti-bacterial, and anti-fungal properties. In addition, these compositions can be used as general disinfectants for human use such as in contact lens solutions, mouthwashes, toothpastes, suppositories, or as more generalized disinfectants found in soaps, household cleaning products, paints, water treatments modalities, or can be incorporated into cosmetic, and can be used as vehicles for drug delivery, an adjuvant in a therapeutic formulation, or as a preservative. These compounds can be delivered in a liquid or solid dosage form and can be incorporated into barrier devices such as condoms, diaphragms, or cervical caps, to help prevent the transmission of STDs. The compounds of this invention can also be used in combination therapies with other classes of antiviral, antibacterial, or antifungal agent having similar or differing mechanisms of action including, but not limited to, anionic or cationic polymers, copolymers, or oligomers, surfactants, protease inhibitors, DNA or RNA polymerase inhibitors (including reverse transcriptase inhibitors), fusion inhibitors, cell wall biosynthesis inhibitors, integrase inhibitors, or virus or bacterial attachment inhibitors.

The invention provides a herpes simplex virus (HSV) vector that does not express toxic HSV genes in non-complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a transgene for at least 28 days in non-complementing cells. The disclosed vectors include vectors having deletions in the genes ICP0, ICP4, TCP22, TCP27 and TCP47, or alternative inactivating mutations, or vectors which express one or more of these genes with modified kinetics. The invention also relates to viral stocks of the inventive vectors, compositions thereof suitable for use therapeutically or for in vitro applications, and methods relating thereto. In another aspect, the invention provides a complementing cell, in particular a U20S cell, engineered to express ICP4 and ICP27 when the cell is infected with HSV for the production of the inventive vector. Said cells are disclosed as naturally complementing ICP0.

The present invention provides an HSV having a genome with a mutation of a TAATGARAT sequence such that, in the presence of a ICP4 gene product, a native immediate early gene is expressed from the genome with delayed kinetics, the genome having a further inactivating mutation of each of the genes encoding ICP4.

The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g. helicobacter pylori), viral infections (e.g. herpes simplex virus infections) and inflammations, as well as against fissura ani and pruritus ani.

The invention provides a recombinant II type herpes simplex virus vector. An ICP34.5 gene and an ICP47 gene of a wild II type herpes simplex virus HG52 strain are removed in the virus vector, and preferably a human granulocyte macrophage-colony stimulating factor (hGM-CSF) expression box is inserted into the position where the ICP34.5 gene is removed. The invention also provides a preparation method of the recombinant II type herpes simplex virus vector, a recombinant virus using the recombinant II type herpes simplex virus as a vector, a medicinal composition consisting of the recombinant II type herpes simplex virus vector and a pharmaceutically acceptable vector or excipient, and application of the recombinant II type herpes simplex virus vector in preparation of a gene medicament for treating tumors. As the ICP34.5 gene is removed in the recombinant II type herpes simplex virus vector provided by the invention, the oncolysis virus is safe and can selectively grow and propagate in tumor cells; the ICP47 gene is removed to promote immune response and enhance oncolysis activity; and the curative effect of the recombinant II type herpes simplex virus vector is superior to that of the conventional recombinant I type herpes simplex virus vector, and the recombinant II type herpes simplex virus vector has high safety.

The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.

An application of indole-2.3-bione in preparing the antiviral medicine for HIV, influenza virus, hemorrhagic virus and herpes simplex virus and the immunopotentiator is disclosed.

A method of treating cancer in a subject is disclosed, the method comprising administration of an oncolytic herpes simplex virus and administration of lymphocyte cells modified to express a chimeric antigen receptor (CAR) or modified to express a T cell receptor (TCR).

The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and / or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.

The invention provides a real-time fluorescent quantitation PCR (polymerase chain reaction) kit for simultaneously detecting conventional herpesvirus hominises HSV (herpes simplex virus)-1, HSV-2, EBV and HCMV (human cytomegalovinis). The kit consists of quantitation PCR reaction liquid, quantitation reaction liquid, an HSV-1 standard substance, an HSV-2 standard substance, an EBV standard substance, an HCMV standard substance, a negative reference substance, an HSV-1 positive reference substance, an HSV-2 positive reference substance, an EBV positive reference substance, an HCMV positive reference substance, a specification and a kit body. The kit disclosed by the invention adopts a real-time fluorescent quantitation PCR technology and two specific fluorescent probes in the same reaction system; the detection range covers the four most conventional herpesvirus hominises, so that the four herpesvirus hominises in a sample can be simultaneously subjected to parting detection; real-time and accurate quantitation can be realized; the need for early, quick and accurate diagnosis can be met; a powerful basis is supplied to epidemiological investigation and immediate formulation of a targeted treating scheme.